Jun 2026 (Q2 FY26) — Aug 11, 2026
DarioHealth Q2 FY26 — Multi-Condition Platform and AI Drive Future Growth
Read the full callDarioHealth (DRIO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
DarioHealth earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 5.2 | −3.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -125.2 | +46.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$5.13 −5.87% · −$0.32
Performance −64.3% 1Y
1Y: $14.38 on 14 Oct 2025 → $5.13. High $16.19 (24 Oct 2025), low $5.13 (15 Oct 2026).
- Previous close
- $5.45
- 52-week range
- $5.13 – $16.19
- One year
- −62.00%
Overview
- Symbol
- DRIO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
DarioHealth earnings calls (DRIO)
Financials
What the filings say
Net profit, year on year: +39% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 8 | 7 | 5 | 5 | 5 | 6 | 5 |
| Operating profit | -12 | -12 | -9 | -9 | -9 | -9 | -7 | -6 |
| Operating margin | −162.1% | −153.4% | −139.3% | −171.3% | −189.4% | −163.7% | −130.9% | −125.2% |
| Other income | -0 | 2 | 0 | -4 | -1 | -0 | -1 | -1 |
| Interest | — | — | — | — | 1 | 1 | 1 | 1 |
| Profit before tax | -12 | -9 | -9 | -13 | -10 | -9 | -8 | -8 |
| Tax rate | 0.1% | −1.6% | −0.2% | 0.0% | 0.0% | −0.9% | −0.7% | −4.3% |
| Net profit | -12 | -10 | -9 | -13 | -10 | -9 | -8 | -8 |
| EPS ($ per share) | -4.91 | — | -2.87 | -3.54 | -2.96 | — | -1.25 | -0.85 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -89 | -110 | -143 | -222 | -286 | -349 | -390 | -452 |
| Total liabilities | 5 | 6 | 7 | 15 | 39 | 38 | 47 | 42 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Investments | — | — | — | — | — | — | — | 4 |
| Total assets | 14 | 25 | 35 | 101 | 119 | 96 | 119 | 110 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -11 | -16 | -18 | -50 | -48 | -30 | -39 | -26 |
| Cash from investing | -0 | -0 | -2 | -8 | -1 | -1 | -9 | -4 |
| Cash from financing | 19 | 25 | 28 | 66 | 62 | 18 | 39 | 24 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 |
| Free cash flow | -12 | -16 | -18 | -51 | -48 | -31 | -39 | -26 |
Insider filings
9 filings between Jul 23, 2026 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
$100.0K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 8
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Matheis Dennis | $100.0K | — | Jul 23, 2026 |
Latest filings (31)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Franco-Yehuda Chen Chief Financial Officer | Award | 95,000 | $0 |
| Sep 24, 2026 | PALUMBO JOHN R Director | Award | 62,000 | $0 |
| Sep 24, 2026 | STERN ADAM K Director | Award | 28,000 | $0 |
| Sep 24, 2026 | MCGRATH DENNIS M Director | Award | 61,000 | $0 |
| Sep 24, 2026 | Shaked Yoav Director | Award | 54,000 | $0 |
| Sep 24, 2026 | Raphael Erez Chief Executive Officer | Award | 297,000 | $0 |
| Sep 24, 2026 | Karah Hila Director | Award | 28,000 | $0 |
| Sep 24, 2026 | Matheis Dennis Director | Award | 44,000 | $0 |
| Jul 23, 2026 | Matheis Dennis Director | Purchase | 14,430 | $100.0K |
| Sep 18, 2025 | STERN ADAM K Director | Conversion | 11,760 | $475.1K |
| Sep 18, 2025 | STERN ADAM K Director | Conversion | 8,435 | $140.0K |
| Sep 11, 2025 | Shaked Yoav Director | Award | 20,000 | $0 |
| Sep 11, 2025 | STERN ADAM K Director | Award | 20,000 | $0 |
| Sep 11, 2025 | Nelson Steven Charles President and CCO | Award | 30,000 | $0 |
| Sep 11, 2025 | MCGRATH DENNIS M Director | Award | 20,000 | $0 |
| Sep 11, 2025 | Franco-Yehuda Chen Chief Financial Officer | Award | 5,000 | $0 |
| Sep 11, 2025 | Leisure Lawrence B. Director | Award | 20,000 | $0 |
| Sep 11, 2025 | Raphael Erez Chief Executive Officer | Award | 60,000 | $0 |
| Sep 11, 2025 | Matheis Dennis Director | Award | 20,000 | $0 |
| Sep 11, 2025 | Karah Hila Director | Award | 20,000 | $0 |
| Aug 27, 2025 | Nelson Steven Charles President and CCO | Purchase | 40,000 | $21.2K |
| Feb 24, 2025 | KAPLAN JON H. Director | Award | 30,000 | $0 |
| Nov 12, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.5K |
| Sep 11, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.0K |
| Sep 10, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.2K |
| Sep 9, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.0K |
| Sep 6, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.2K |
| Sep 5, 2024 | Nelson Steven Charles Chief Commercial Officer | Purchase | 5,000 | $4.1K |
| Aug 12, 2024 | Shaked Yoav Director | Conversion | 772 | $14.7K |
| Aug 12, 2024 | Raphael Erez Chief Executive Officer | Conversion | 579 | $11.1K |
| Aug 12, 2024 | Matheis Dennis Director | Conversion | 965 | $18.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for DarioHealth Corp.
Free account. Everything above stays public.
Write why you follow DarioHealth Corp. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading